Universität zu Köln

Barta, Stefan K., Xue, Xiaonan, Wang, Dan, Lee, Jeannette Y., Kaplan, Lawrence D., Ribera, Josep-Maria, Oriol, Albert ORCID: 0000-0001-6804-2221, Spina, Michele ORCID: 0000-0001-6576-8182, Tirelli, Umberto, Boue, Francois, Wilson, Wyndham H., Wyen, Christoph, Dunleavy, Kieron, Noy, Ariela ORCID: 0000-0002-3001-4898 and Sparano, Joseph A. (2014). A new prognostic score for AIDS-related lymphomas in the rituximab-era. Haematologica, 99 (11). S. 1731 - 1738. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Full text not available from this repository.

Abstract

While the International Prognostic Index is commonly used to predict outcomes in immunocompetent patients with aggressive B-cell non-Hodgkin lymphomas, HIV-infection is an important competing risk for death in patients with AIDS-related lymphomas. We investigated whether a newly created prognostic score (AIDS-related lymphoma International Prognostic Index) could better assess risk of death in patients with AIDS-related lymphomas. We randomly divided a dataset of 487 patients newly diagnosed with AIDS-related lymphomas and treated with rituximab-containing chemoimmunotherapy into a training (n=244) and validation (n=243) set. We examined the association of HIV-related and other known risk factors with overall survival in both sets independently. We defined a new score (AIDS-related lymphoma International Prognostic Index) by assigning weights to each significant predictor [age-adjusted International Prognostic Index, extranodal sites, HIV-score (composed of CD4 count, viral load, and prior history of AIDS)] with three risk categories similar to the age-adjusted International Prognostic Index (low, intermediate and high risk). We compared the prognostic value for overall survival between AIDS-related lymphoma International Prognostic Index and age-adjusted International Prognostic Index in the validation set and found that the AIDS-related lymphoma International Prognostic Index performed significantly better in predicting risk of death than the age-adjusted International Prognostic Index (P=0.004) and better discriminated risk of death between each risk category (P=0.015 vs. P=0.13). Twenty-eight percent of patients were defined as low risk by the ARL-IPI and had an estimated 5-year overall survival (OS) of 78% (52% intermediate risk, 5-year OS 60%; 20% high risk, 5-year OS 50%).

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Barta, Stefan K. UNSPECIFIED UNSPECIFIED UNSPECIFIED Xue, Xiaonan UNSPECIFIED UNSPECIFIED UNSPECIFIED Wang, Dan UNSPECIFIED UNSPECIFIED UNSPECIFIED Lee, Jeannette Y. UNSPECIFIED UNSPECIFIED UNSPECIFIED Kaplan, Lawrence D. UNSPECIFIED UNSPECIFIED UNSPECIFIED Ribera, Josep-Maria UNSPECIFIED UNSPECIFIED UNSPECIFIED Oriol, Albert UNSPECIFIED orcid.org/0000-0001-6804-2221 UNSPECIFIED Spina, Michele UNSPECIFIED orcid.org/0000-0001-6576-8182 UNSPECIFIED Tirelli, Umberto UNSPECIFIED UNSPECIFIED UNSPECIFIED Boue, Francois UNSPECIFIED UNSPECIFIED UNSPECIFIED Wilson, Wyndham H. UNSPECIFIED UNSPECIFIED UNSPECIFIED Wyen, Christoph UNSPECIFIED UNSPECIFIED UNSPECIFIED Dunleavy, Kieron UNSPECIFIED UNSPECIFIED UNSPECIFIED Noy, Ariela UNSPECIFIED orcid.org/0000-0002-3001-4898 UNSPECIFIED Sparano, Joseph A. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-425157
DOI:	10.3324/haematol.2014.111112
Journal or Publication Title:	Haematologica
Volume:	99
Number:	11
Page Range:	S. 1731 - 1738
Date:	2014
Publisher:	FERRATA STORTI FOUNDATION
Place of Publication:	PAVIA
ISSN:	0390-6078
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language NON-HODGKIN-LYMPHOMA; ACTIVE ANTIRETROVIRAL THERAPY; VIRUS-INFECTION STATUS; LARGE-CELL LYMPHOMA; BURKITTS-LYMPHOMA; INTENSIVE CHEMOTHERAPY; SURVIVAL; LEUKEMIA; CONSORTIUM; MALIGNANCY Multiple languages Hematology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/42515